Home > Neurology > ECF 2020 > ECF Round-Up Articles > Superior effect of ponesimod versus teriflunomide on clinical disease activity and MRI-based outcomes

Superior effect of ponesimod versus teriflunomide on clinical disease activity and MRI-based outcomes

Conference
ECF 2020
Trial
Phase 3, OPTIMUM
In the phase 3 OPTIMUM study, ponesimod showed benefit compared with teriflunomide on all MRI outcomes, including brain volume loss. A significantly higher proportion of patients achieved NEDA-3 and NEDA-4 status. These findings support the previously observed effect of ponesimod on clinical endpoints in patients with relapsing MS. Ponesimod is an orally active, selective sphingosine-1-phosphate receptor modulator that causes dose-dependent sequestration of lymphocytes in lymphoid organs, thereby reducing the blood count. In the phase 3 OPTIMUM study (NCT02425644), ponesimod demonstrated superior efficacy compared to teriflunomide in reducing annualised relapse rate (ARR) in patients with relapsing-remitting MS. The current analysis of the OPTIMUM study evaluated prespecified MRI-based endpoints and ‘no evidence of disease activity’ (NED...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on